2 lectures · 129 items
Global guideline on the use of GLP-1 medicines in treating obesity issued by WHO
EU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular Health
GPcardio and ACC’s NCD Academy Join Forces to Strengthen Primary Care in Cardiovascular Disease Prevention
Global Shift: From Underweight to Obesity Dominance in Three Decades Across Generations
Slides | Take home messages of EPCCS Guidance on 'Current management of diabetes and CV risk in primary care'
Шляхи стимулювання модифікації способу життя з метою зменшення серцево-судинного ризику на первинній ланці медичної допомоги
Stimulating health behaviour changes to reduce cardiovascular risk in primary careThis review outlines a practical framework for integrating GLP-1 receptor agonists, SGLT2 inhibitors, and mineralocorticoid receptor antagonists into maintenance immunosuppression for kidney…
a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide.
This meta-analysis of seven RCTs involving 38,412 patients evaluated the impact of semaglutide on cardiovascular mortality across type 2 diabetes, overweight/obesity, and HFpEF populations…
In a prospective UK Biobank cohort of 438,748 participants, researchers evaluated the joint impact of metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia-related…
ziltivekimab cuts IL-6 by 76 and hsCRP by 64 percent, but heart attack, stroke and death are unchanged in 6,376 patients with atherosclerosis, kidney disease and inflammation
Presented in LBS.01 at AHA 2026 (Saturday 7 November) by Paul Ridker and published simultaneously in NEJM. ZEUS randomised 6,376 patients (3,184 ziltivekimab, 3,192 placebo; mean age 69.4, 27.5…
A prespecified secondary analysis of the landmark FLOW trial confirmed that once-weekly semaglutide 1.0 mg is safe and well-tolerated across the spectrum of chronic kidney disease severity in…
This review examines the renal protective effects of GLP-1 receptor agonists and newer multi-hormone receptor modulators in patients with non-diabetic chronic kidney disease. Benefits arise through…
Mission Impossible-or Not Too Late to Start?
This narrative review evaluates the evidence for four-pillar therapy (RAS inhibitors, SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists) in patients with type 2 diabetes and advanced chronic…
A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of 31 studies (26,948 patients) compared fixed and age-dependent NT-proBNP thresholds for diagnosing acute heart failure in dyspneic emergency department…
SURPASS-CVOT analysis.
In a post-hoc analysis of the SURPASS-CVOT trial, patients with type 2 diabetes and established atherosclerotic cardiovascular disease received either tirzepatide or dulaglutide over a mean follow-up…
A large real-world propensity-matched cohort study (N=271,685 per arm) compared cardiovascular outcomes in patients with type 2 diabetes treated with tirzepatide versus semaglutide. Tirzepatide was…
A global perspective.
A systematic review of 109 global clinical guidelines reveals a shared framework for lipid management in adults with or at risk of ASCVD, yet significant discrepancies persist regarding LDL-C targets…
A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.
This meta-analysis of 14 trials (n=15,882) demonstrates that GLP-1 receptor agonists significantly reduce MACE (HR 0.79), heart failure hospitalizations (HR 0.48), and all-cause mortality (HR 0.75)…
